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Background: Bipolar disorder is associated with an increased risk of aggression. However, 
effective management of hostility and/or agitation symptoms may prevent patients from 
becoming violent. This analysis investigated the efficacy of the antipsychotic asenapine on 
hostility and agitation in patients with bipolar I disorder.
Methods: Data were pooled from three randomized, double-blind, placebo-controlled, Phase III 
trials of asenapine in adults with manic or mixed episodes of bipolar I disorder (NCT00159744, 
NCT00159796, and NCT00764478). Post hoc analyses assessed the changes from baseline to 
day 21 on the Young Mania Rating Scale (YMRS) and the Positive and Negative Syndrome 
Scale (PANSS) hostility-related item scores in asenapine- or placebo-treated patients with at 
least minimal or mild symptom severity and on the PANSS-excited component (PANSS-EC) 
total score in agitated patients. Changes were adjusted for improvements in overall mania 
symptoms to investigate direct effects on hostility.
Results: Significantly greater changes in favor of asenapine versus placebo were observed in 
YMRS hostility-related item scores (irritability: least squares mean difference [95% confidence 
interval] =-0.5 [-0.87, -0.22], P=0.001; disruptive–aggressive behavior: -0.7 [-0.99, -0.37], 
P0.0001), PANSS hostility item score (-0.2 [-0.44, -0.04]; P=0.0181), and PANSS-EC total 
score (-1.4 [-2.4, -0.4]; P=0.0055). Changes in the YMRS disruptive–aggressive behavior score 
and the sum of the hostility-related items remained significant after adjusting for improvements 
in other YMRS item scores.
Conclusion: Asenapine significantly reduced hostility and agitation in patients with bipolar I 
disorder; improvement was at least partially independent of overall improvement on mania 
symptoms.
Keywords: asenapine, hostility, bipolar disorder, agitation, mania, aggression
Introduction
Violent/aggressive behavior in psychiatric patients is a public health problem associated 
with significant medical, emotional, and financial costs to patients, caregivers, and 
society.1 Aggressive behavior, defined as overt action intended to harm,1 is frequently 
observed in patients with bipolar disorder, particularly in those with comorbid sub-
stance abuse.1–4 In patients with bipolar disorder, aggressive behavior has been linked 
to comorbid personality disorder, history of childhood trauma, and the severity of 
current manic or depressive symptoms.5 Because patients with bipolar disorder are 
at high risk of becoming violent during acute manic episodes,6,7 treatment of at-risk 
patients before their symptoms progress to violence is critical.
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Behaviors such as hostility and agitation can be used 
to identify patients who are at risk of aggressive behavior. 
Hostility denotes unfriendly attitudes, including irritability, 
anger, resentment, and verbal aggression.1 Although not vio-
lent behavior per se, hostility can escalate into violence and 
is correlated with an increased risk of aggression and treat-
ment nonadherence in patients with psychiatric disorders.1,8 
Similarly, agitation, which is defined as excessive verbal 
or motor activity, can also escalate to aggressive behavior9 
and is frequently observed in patients with bipolar disorder 
who are experiencing a manic episode.1 Due to the risk of 
hostility and agitation leading to violent behavior, effective 
management of these conditions is necessary to ensure patient 
safety and to prevent harm to others.
Current treatments to manage hostility and agitation in 
patients with bipolar disorder who are experiencing a manic 
episode include benzodiazepines and antipsychotics.1,10 
Post hoc analyses of data from the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) study in patients 
with schizophrenia suggested that some second-generation 
antipsychotics may have specific effects on hostility, indepen-
dent of their effects on positive schizophrenia symptoms.11 
Importantly, some of these antipsychotics have been shown 
to have similar effects on hostility and agitation in patients 
with bipolar disorder.12–14
The second-generation antipsychotic asenapine is US 
Food and Drug Administration approved in the USA for 
acute and maintenance treatment of schizophrenia and for 
acute and maintenance treatment of bipolar I disorder in 
adults. Asenapine monotherapy has demonstrated efficacy in 
three positive, randomized, double-blind, placebo-controlled, 
Phase III trials in adults with manic or mixed episodes associ-
ated with bipolar I disorder.15–17 Unlike other antipsychotics, 
asenapine is administered as a fast-dissolving sublingual tab-
let twice daily (BID). In a randomized, double-blind, placebo-
controlled trial in patients with any diagnosis experiencing 
acute agitation in an emergency room setting, sublingual 
asenapine demonstrated efficacy in treating agitation, with an 
effect size (ES) comparable to that observed in a prior study 
of intramuscular antipsychotics,18 suggesting that it may 
have efficacy as a noninvasive method of managing hostile 
and agitated behaviors in patients with bipolar disorder. To 
better characterize the effects of asenapine on hostility and 
agitation in patients experiencing a manic or mixed episode 
associated with bipolar I disorder, post hoc analyses based 
on Young Mania Rating Scale (YMRS)19 and Positive and 
Negative Syndrome Scale (PANSS)20 items related to hos-
tility and agitation were conducted on pooled data from the 
three double-blind, randomized studies.
Methods
study design
Data were pooled from three similarly designed, 3-week, 
multicenter, positive, randomized, double-blind, placebo-
controlled, Phase III trials of asenapine in adult patients with 
manic or mixed episodes associated with bipolar I disorder 
(NCT00159744, NCT00159796, and NCT00764478). The 
data accessed from these trials are on file with the study 
sponsor. Detailed methods of the component studies have 
been previously published.15–17 In brief, trials included a 
run-in period of up to 7 days and 3 weeks of double-blind 
treatment. Two studies used flexible-dose designs in which 
patients were randomized 2:1:2 to asenapine, placebo, and 
olanzapine (included for assay sensitivity). The starting 
asenapine dose was 10 mg BID on day 1; thereafter, patients 
received 5 or 10 mg BID. The third study used a fixed-dose 
design, and patients were randomized 1:1:1 to placebo, 
asenapine 5 mg BID, or asenapine 10 mg BID. Each compo-
nent study was approved by an institutional review board and 
conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice guidelines. All participants provided 
written informed consent.
Patients
The studies included male and female patients (18 years 
old) with a primary diagnosis of bipolar I disorder according 
to Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition (DSM-IV)21 criteria who were experiencing 
a manic or mixed episode. The Mini-International Neurop-
sychiatric Interview22 was used to confirm the diagnosis; 
mania severity was determined using the YMRS. Clinical 
inclusion criteria included YMRS total score 20 at screen-
ing and baseline, a current manic or mixed bipolar I episode 
that began 3 months (flexible-dose studies) or 1 month 
(fixed-dose study) prior to screening, and a documented 
history of 1 previous moderate-to-severe manic or mixed 
episodes, with or without psychotic features.
Typical exclusion criteria for bipolar I disorder studies 
were applied. Patients with any other psychotic disorders, 
primary axis I diagnosis other than bipolar I disorder, cur-
rent diagnosis of substance abuse/dependence, history of 
rapid cycling, and who were at imminent risk of harm to 
self or others were excluded. Use of antipsychotics, depot 
neuroleptics, antidepressants, mood stabilizers, and other 
psychotropic drugs was prohibited; drugs for extrapyramidal 
symptoms (eg, beta-blockers and anticholinergics), agitation 
(eg, lorazepam and diazepam), and insomnia (eg, temazepam, 
zolpidem, and zaleplon) were allowed during screening and 
for the first 7 days after randomization only.
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Post hoc analyses
Analyses were based on pooled data from the three com-
ponent studies. The full analysis set (FAS) comprised data 
from all randomized patients who received at least one dose 
of trial medication and had both baseline and 1 post-
baseline YMRS total score assessments. Asenapine doses 
(5 or 10 mg BID) were combined for the pooled analysis. 
To evaluate the effects of asenapine on hostility in patients 
with a manic or mixed episode associated with bipolar I 
disorder, post hoc analyses were performed in subgroups 
of patients with hostility symptoms defined by cutoff scores 
on hostility-related items from the YMRS or PANSS. The 
YMRS hostility subgroup included patients with base-
line scores 2 on the YMRS hostility-related items (ie, 
disruptive-aggressive behavior and irritability); the PANSS 
hostility subgroup included patients with baseline scores 2 
on the PANSS hostility item (P7). YMRS total scores and 
scores on individual items were assessed in both the YMRS 
and PANSS hostility subgroups. PANSS hostility item scores 
were assessed in the PANSS hostility subgroup.
To characterize the effects of asenapine on agitation, 
changes from baseline in PANSS-excited component 
(PANSS-EC) total scores were evaluated in agitated patients 
treated with asenapine or placebo. The PANSS-EC comprises 
the following five PANSS items: tension (G4), uncooperative-
ness (G8), poor impulse control (G14), excitement (P4), and 
hostility (P7).23 PANSS-EC agitation subgroup patients were 
defined as those having a PANSS-EC total score 14 and one 
or more individual PANSS-EC item scores 4 at baseline. 
The percentage of patients who achieved response (ie, 40% 
decrease from baseline to endpoint) in PANSS-EC total score 
was also determined.
statistical analyses
Least squares (LS) mean changes from baseline to day 21 in 
YMRS total score and individual item scores were assessed 
for asenapine- and placebo-treated patients in the YMRS and 
PANSS hostility subgroups. LS mean change in the PANSS 
hostility item score was assessed in the PANSS hostility 
subgroup; LS mean change in the PANSS-EC total score 
was assessed in the PANSS-EC agitation subgroup. LS mean 
differences (LSMDs) with 95% confidence intervals (CIs) 
for asenapine versus placebo were used to evaluate changes 
from baseline in efficacy parameters. Analyses were based 
on a mixed-effects model for repeated measures (MMRM) 
approach with an unstructured covariance matrix with base-
line, pooled site, treatment, and visit-by-treatment interaction 
as fixed effects. LS means at day 21 were estimated using 
this MMRM model, and including early visit data based on 
the assumption of missing at random. For the PANSS-EC 
responder analysis, a logistic regression model with study 
and treatment as factors and baseline PANSS-EC score as a 
covariate was used, with missing values imputed based on 
a multiple imputation method.
To distinguish between specific improvements in 
hostility symptoms and general improvements in overall 
mania symptoms, separate analyses were conducted using 
a similar MMRM model with additional covariates to 
correct for potential confounder variables. On the YMRS 
disruptive-aggressive behavior score, the irritability item 
score, and the sum of the disruptive–aggressive behavior 
and irritability item scores, analyses were conducted after 
adjusting for the sum changes of the other nine individual 
YMRS items. Similarly, analyses were conducted on the 
PANSS hostility item scores after adjusting for scores on 
the PANSS positive symptom items (delusions [P1], con-
ceptual disorganization [P2], hallucinatory behavior [P3], 
grandiosity [P5], suspiciousness/persecution [P6], and 
unusual thought content [G9]). Additional analyses were 
conducted after adjusting for the PANSS positive symptom 
items and sedation (as measured by the presence of an 
adverse event of sedation, somnolence, or hypersomnia) 
as covariates.
ESs were calculated using Cohen’s d and were based 
on the difference between treatment group means divided 
by the pooled standard deviation from the two treatment 
groups. All tests for LSMD were two sided at the 5% 
significance level; P-values were not adjusted for multiple 
comparisons.
Results
Pooled baseline characteristics
Data from 929 patients were included in the pooled FAS 
(pooled asenapine =605 patients; placebo =324 patients). The 
YMRS hostility subgroup included data from 741 patients at 
baseline (pooled asenapine =481; placebo =260). The PANSS 
hostility subgroup included data from 693 patients at baseline 
(pooled asenapine =455 patients; placebo =238 patients), and 
the PANSS-EC agitation subgroup included 349 patients 
(pooled asenapine =233 patients; placebo =116 patients). Base-
line scores on YMRS or PANSS items/factors related to 
agitation or hostility were similar between treatment groups 
(Table 1). Among all patients in the component trials, the 
most commonly used concomitant medications for agita-
tion were lorazepam (placebo, 26.7%; asenapine, 24.0%) 
and diazepam (placebo, 1.5%; asenapine, 1.0%); no other 
individual concomitant medications were administered for 
agitation in 0.5% of patients.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
64
.1
18
.2
23
.1
96
 o
n 
05
-J
un
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2958
citrome et al
YMrs hostility subgroup
For patients in the YMRS hostility subgroup, baseline YMRS 
total score and baseline scores on all 11 YMRS items were 
similar between treatment groups (Table 2). A significantly 
greater change from baseline to day 21 on YMRS total score 
was observed with asenapine versus placebo (ES =0.45, 
P0.0001) (Table 2). Significantly larger changes from base-
line in favor of asenapine were also observed on both YMRS 
Table 1 Baseline scores on efficacy scales and items related to hostility and agitation
Efficacy scale Placebo 
patients (n)
Placebo, mean (SD) Asenapine 
patients (n)
Asenapine, mean (SD)
YMrs hostility subgroupa
YMrs total score 260 30.2 (5.94) 481 30.3 (5.97)
YMrs disruptive–aggressive behavior item score 260 3.3 (1.31) 481 3.3 (1.22)
YMrs irritability item score 260 4.1 (1.14) 481 4.1 (1.20)
PaNss total score 259 64.5 (17.37) 476 62.8 (15.41)
PaNss positive subscale score 259 18.2 (5.74) 476 17.8 (5.24)
PaNss hostility item (P7) score 259 2.7 (1.19) 476 2.7 (1.18)
PaNss-ec score 259 13.6 (3.72) 476 13.6 (3.75)
PaNss hostility subgroupb
YMrs total score 236 29.8 (6.02) 452 29.9 (6.08)
YMrs disruptive–aggressive behavior item score 236 3.1 (1.51) 452 3.1 (1.45)
YMrs irritability item score 236 4.0 (1.30) 452 4.0 (1.29)
PaNss total score 238 66.5 (17.04) 455 64.7 (15.12)
PaNss positive subscale score 238 18.9 (5.54) 455 18.5 (4.96)
PaNss hostility item (P7) score 238 3.1 (0.93) 455 3.0 (0.94)
PaNss-ec score 238 14.2 (3.31) 455 14.1 (3.43)
PaNss-ec agitation subgroupc
YMrs total score 115 31.9 (6.36) 232 32.4 (6.21)
YMrs disruptive–aggressive behavior item score 115 3.6 (1.48) 232 3.5 (1.43)
YMrs irritability item score 115 4.5 (1.29) 232 4.4 (1.36)
PaNss total score 116 75.0 (17.04) 233 71.2 (14.84)
PaNss positive subscale score 116 21.8 (5.77) 233 20.8 (5.19)
PaNss hostility item (P7) score 116 3.4 (1.14) 233 3.4 (1.15)
PaNss-ec score 116 16.8 (2.67) 233 16.7 (2.60)
Notes: aYMrs hostility subgroup comprised patients with baseline YMrs hostility-related item scores 2. bPaNss hostility subgroup comprised patients with baseline 
PaNss hostility item scores 2. cPaNss-ec agitation subgroup comprised patients with PaNss-ec score 14, and one or more individual PaNss-ec item scores 4 at 
baseline.
Abbreviations: PaNss, Positive and Negative syndrome scale; PaNss-ec, PaNss-excited component; sD, standard deviation; YMrs, Young Mania rating scale.
Table 2 change from baseline to day 21 in YMrs total score and individual items in the YMrs hostility subgroupa (MMrM)
Placebo (n=260) Asenapine (n=481) Asenapine vs placebo
Baseline 
mean (SD)
LS mean 
change (SE)
Baseline 
mean (SD)
LS mean 
change (SE)
LSMD  
(95% CI)
ES P-value
YMrs total score 30.2 (5.94) -9.7 (0.76) 30.3 (5.97) -14.0 (0.55) -4.3 (-6.16, -2.54) 0.45 0.0001
YMrs items
Disruptive–aggressive behavior 3.3 (1.31) -0.9 (0.13) 3.3 (1.22) -1.5 (0.09) -0.7 (-0.99, -0.37) 0.45 0.0001
irritability 4.1 (1.14) -1.3 (0.14) 4.1 (1.20) -1.9 (0.10) -0.5 (-0.87, -0.22) 0.32 0.0010
appearance 1.2 (0.84) -0.4 (0.06) 1.2 (0.90) -0.6 (0.04) -0.2 (-0.30, -0.01) 0.21 0.0329
insight 1.0 (1.29) -0.2 (0.06) 1.0 (1.31) -0.3 (0.04) -0.2 (-0.30, -0.02) 0.22 0.0286
language–thought disorder 2.3 (0.62) -0.8 (0.07) 2.2 (0.66) -1.0 (0.05) -0.2 (-0.35, -0.00) 0.19 0.0475
increased motor activity–energy 2.9 (0.71) -1.1 (0.09) 2.9 (0.64) -1.4 (0.07) -0.3 (-0.52, -0.09) 0.24 0.0052
elevated mood 2.6 (0.95) -0.9 (0.08) 2.8 (0.88) -1.3 (0.06) -0.4 (-0.65, -0.24) 0.39 0.0001
sleep 2.4 (0.90) -0.8 (0.09) 2.4 (0.89) -1.2 (0.06) -0.4 (-0.64, -0.23) 0.32 0.0001
sexual interest 1.6 (1.18) -0.6 (0.08) 1.6 (1.16) -0.8 (0.06) -0.3 (-0.44, -0.07) 0.24 0.0076
content 4.4 (2.24) -1.5 (0.16) 4.3 (2.11) -2.2 (0.11) -0.6 (-1.01, -0.27) 0.26 0.0008
speech 4.4 (1.55) -1.8 (0.15) 4.4 (1.57) -2.3 (0.11) -0.5 (-0.82, -0.11) 0.28 0.0101
Note: aPatients with baseline YMrs hostility-related item scores 2.
Abbreviations: CI, confidence interval; ES, effect size; LS, least squares; LSMD, LS mean difference; MMRM, mixed-effects model for repeated measures; SD, standard 
deviation; se, standard error of the mean; YMrs, Young Mania rating scale.
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hostility item scores in these patients (irritability: ES =0.32, 
P=0.001; disruptive–aggressive behavior: ES =0.45, 
P0.0001) (Figure 1 and Table 2). For the remaining YMRS 
items, significantly larger changes from baseline to day 21 
were observed for asenapine compared to placebo, with ES 
ranging from 0.19 to 0.39 (Table 2). Similar results were 
observed on the YMRS total and item scores in the PANSS 
hostility subgroup (Table S1).
Following adjustment for the sum of the other nine 
YMRS items, the difference in change from baseline 
remained statistically significant in favor of asenapine versus 
placebo on the disruptive–aggressive behavior score 
(LSMD [95% CI] =-0.4 [-0.62, -0.09], P=0.0081) and 
the sum of the disruptive–aggressive behavior and irrita-
bility scores (-0.6 [-1.06, -0.09], P=0.0203) (Figure 1). 
Differences between asenapine and placebo did not meet 
statistical significance on the irritability item score (-0.2 
[-0.48, 0.07], P=0.1412) following adjustment for other 
mania symptoms.
PaNss hostility and PaNss-ec agitation 
subgroups
Baseline PANSS hostility item scores were similar between 
treatment groups (Table 1). In the PANSS hostility sub-
group, the difference between asenapine and placebo was 
statistically significant on the PANSS hostility item score at 
day 21 (LSMD [95% CI] =-0.2 [-0.44, -0.04]; P=0.0181) 
(Figure 2A). A significant difference in favor of asenapine 
was also evident at day 7 (-0.3 [-0.47, -0.12]; P=0.0010) 
but was lost at day 14 (-0.1 [-0.39, 0.15]; P=0.3946). After 
adjustment for improvements in PANSS positive symptoms, 
significant changes from baseline in favor of asenapine were 
observed at day 7 (-0.2 [-0.37, -0.04]; P=0.0151) but not 
at day 21 (-0.1 [-0.32, 0.05], P=0.1582). Similarly, after 
adjustment for improvements in PANSS positive symptoms 
and sedation, a statistically significant difference was noted 
for asenapine versus placebo at day 7 (-0.2 [-0.38, -0.04]; 
P=0.0171) but not at day 21 (-0.1 [-0.33, 0.06]), P=0.1634). 
Similar results on both the unadjusted and adjusted PANSS 
hostility item scores were observed in the YMRS hostility 
subgroup (data not shown).
Baseline PANSS-EC total scores in the PANSS-EC 
agitation subgroup were similar between treatment groups 
(Table 1). Statistically significant changes from baseline to 
day 21 in favor of asenapine versus placebo were observed 
on the PANSS-EC total score in agitated patients (ES =0.25, 
P0.01) (Figure 2B). PANSS-EC response (ie, 40% 
improvement from baseline at day 21) was achieved by 
24/115 (20.9%) placebo- and 75/232 (32.3%) asenapine-
treated patients in the PANSS-EC agitation subgroup 
Figure 1 changes from baseline to day 21 in YMrs hostility-related items in the YMrs hostility subgroup.
Notes: Patients in this subgroup had baseline YMrs hostility-related item scores 2. *P0.05; **P0.01, ***P0.001. error bars indicate the standard error of the mean.
Abbreviations: LS, least squares; YMRS, Young Mania Rating Scale.
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(odds ratio [95% CI] =1.64 [0.91, 2.94], P=0.099; number 
needed to treat [NNT] =9 [95% CI 5, 53]).
Discussion
Asenapine produced an antihostility effect in patients with 
bipolar I disorder and symptoms of hostility, as determined by 
multiple measures of hostility and agitation. Compared with 
placebo-treated patients, asenapine-treated patients had sig-
nificantly greater improvements on YMRS hostility-related 
items (ie, irritability and disruptive–aggressive behavior), 
as well as the PANSS hostility item at day 21. Significantly 
greater improvement in overall mania symptoms, as mea-
sured by YMRS total score and the YMRS items, was also 
seen in asenapine- versus placebo-treated patients. Improve-
ments in the YMRS disruptive–aggressive behavior item and 
the sum of the disruptive–aggressive behavior and irritability 
items remained significant in favor of asenapine even after 
controlling for improvements in other mania symptoms, sug-
gesting that improvements in these symptom domains were 
independent of general improvements in mania. Additionally, 
significantly greater improvements in symptoms of agitation, 
as measured by changes from baseline in PANSS-EC total 
score, were observed with asenapine versus placebo. Taken 
together, these post hoc analyses using different measures of 
agitation and hostility suggest that asenapine may be an effec-
tive treatment for these symptoms in patients experiencing 
an acute manic or mixed episode of bipolar I disorder.
Interestingly, although changes in the PANSS hostility 
item significantly differed between asenapine- and placebo-
treated patients with high baseline hostility scores at day 
21, these changes were not significantly different after 
adjusting for positive symptoms and sedation. In a study of 
the validity of individual PANSS items, hostility displayed 
overlap between other PANSS items (eg, uncooperativeness, 
hallucinatory behavior), suggesting that it may be poorly 
differentiated; additional significant overlap within the 
individual scores (ie, -3 to +3) suggests that this item may 
also be inherently difficult for raters.24 Furthermore, as the 
component studies were not designed to assess hostility, it 
is also possible that symptoms of hostility may have been 
overlooked, causing scores on that particular item to be 
less precise.
Our findings of antiagitation effects for asenapine are 
supported by a previous double-blind study of asenapine in 
acutely agitated patients with any diagnosis, which showed 
significantly greater improvements in PANSS-EC at 2 hours 
for patients treated with a single dose of asenapine (10 mg) 
compared with patients treated with placebo (P0.001).18 
In that study, the effect of asenapine was rapid, with statis-
tically significant differences versus placebo seen as early 
as 15 minutes after asenapine administration (P0.002). 
Efficacy for asenapine was also supported by significantly 
greater PANSS-EC response rates (40% reduction in 
PANSS-EC) for asenapine-treated patients (78%) than for 
Figure 2 changes from baseline to day 21 in PaNss-derived scores (MMrM).
Notes: (A) PaNss hostility item (P7) score changes in the PaNss hostility subgroup (patients with baseline hostility item scores 2). (B) PaNss-ec total score changes 
in the PaNss-ec agitation subgroup (patients with PaNss-ec total score 14 and score 4 on 1 individual item at baseline). error bars indicate the standard error of 
the mean. *P0.05; **P0.01.
Abbreviations: LS, least squares; MMRM, mixed-effects model for repeated measures; PANSS, Positive and Negative Syndrome Scale; PANSS-EC, PANSS-excited 
component.
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placebo-treated patients (33%) (P0.0001; NNT =3).18 
Although the current post hoc analyses were not designed to 
investigate the rapid effect of asenapine, our results extend 
the findings from acutely agitated patients and suggest that 
BID doses of asenapine over 3 weeks of treatment were 
effective against symptoms of agitation and hostility in 
patients with bipolar I disorder. A small, prospective, natu-
ralistic study conducted on an inpatient psychiatric unit was 
also supportive of the effects of asenapine on agitation and 
aggression. In that study, treatment with asenapine (three 
patients with schizophrenia and two patients with bipolar 
disorder) was associated with a significant reduction in total 
aggression as measured by the Modified Overt Aggression 
Scale, including physical aggression, compared to treatment 
that did not include asenapine.25
Our findings are consistent with findings from previous 
studies of atypical antipsychotics used to treat patients with 
bipolar disorder and symptoms of hostility or agitation. 
Aripiprazole and quetiapine monotherapy demonstrated anti-
hostility effects in patients with bipolar disorder via improve-
ment on YMRS hostility-related items after 3 and 12 weeks 
of treatment, respectively.13,26 Additionally, olanzapine, 
quetiapine, loxapine, and aripiprazole have demonstrated 
efficacy in the rapid treatment of agitation in acutely agitated 
patients with bipolar mania, as measured by improvements 
in the PANSS-EC subscale.10,12,14,27–29
Effective management of hostility and agitation in 
psychiatric patients includes the short-term relief of acute 
symptoms, as well as the prevention of acute episodes of 
hostile/aggressive behavior in the long term.9 Although oral 
antipsychotics are a comprehensive, long-term treatment 
option for bipolar disorder and symptoms of agitation and 
hostility, there is concern that orally administered agents may 
not have a sufficiently rapid onset of action to treat acute or 
emergent behaviors. Asenapine, which is approved for acute 
and maintenance treatment of bipolar disorder, may be unique 
in offering both a rapidly absorbed, noninvasive method of 
administration and acute and longer term antihostility effects. 
Therefore, asenapine is a comprehensive treatment option 
that may be preferable to other antipsychotics in patients 
with bipolar disorder and symptoms of hostility and agita-
tion; however, direct head-to-head comparisons with other 
antipsychotics would be desirable.
The pharmacological profile of asenapine may underlie its 
neurochemical effects and its efficacy on hostile and aggres-
sive behavior. It has been proposed that greater antagonist 
affinity at D
4
 receptors compared to D
2
 receptors (ie, D
4
/D
2
 
affinity ratio 1) may confer antiaggression effects and 
may explain why some medications display greater efficacy 
for these behaviors.30 Asenapine has slightly higher binding 
affinity with D
4
 receptors than D
2
 receptors,31 and this D
4
/D
2
 
ratio may therefore be involved in the antiaggression and 
antihostility effects seen in these analyses.18,30 In addition to 
dopamine receptor affinity, the high affinity of asenapine for 
5-HT
2A
 receptors may play a role in antiaggressive efficacy.31 
Previous studies have shown that antagonism at 5-HT
2A
 
receptors reduces aggressive behavior in preclinical models32 
as well as in patients with neuropsychiatric disorders.33
Limitations of these analyses include their post hoc nature, 
pooled design, and lack of active comparator. Due to the short 
duration of the pooled studies, the full effect of asenapine 
may not have been established. As is common in descriptive 
analyses, P-values were not adjusted for multiple comparisons. 
Patients in the current study were not specifically selected for a 
history of hostile/aggressive behavior; hostility in these patients 
was largely determined by verbal expressions of hostility 
and not physical assault. Therefore, these results may not be 
generalizable to other populations, including overtly aggres-
sive patients. Because doses were pooled, it is not possible to 
identify a dose-dependent effect of asenapine on hostility.
Conclusion
Treatment with asenapine was superior to placebo in reducing 
hostility symptoms and agitation in patients with bipolar I 
disorder, suggesting that asenapine may be an effective 
and noninvasive treatment for hostility and agitation in this 
patient population. Improvements on the YMRS hostility 
factor at endpoint with asenapine treatment were independent 
of improvements on the remaining YMRS items, indicating 
that asenapine may have a direct effect on hostility.
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Table S1 change from baseline to day 21 in YMrs total score and individual items in the PaNss hostility subgroupa (MMrM)
Placebo (n=236) Asenapine (n=452) Asenapine vs placebo
Baseline 
mean (SD)
LS mean 
change (SE)
Baseline 
mean (SD)
LS mean 
change (SE)
LSMD  
(95% CI)
ES P-value
YMrs total score 29.8 (6.02) -10.5 (0.79) 29.9 (6.08) -14.6 (0.58) -4.1 (-5.97, -2.25) 0.49 0.0001
YMrs items
Disruptive–aggressive behavior 3.1 (1.51) -0.7 (0.14) 3.1 (1.45) -1.4 (0.10) -0.7 (-0.97, -0.34) 0.38 0.0001
irritability 4.0 (1.30) -1.3 (0.14) 4.0 (1.29) -1.8 (0.10) -0.5 (-0.84, -0.17) 0.32 0.0033
appearance 1.2 (0.86) -0.4 (0.06) 1.2 (0.91) -0.6 (0.05) -0.1 (-0.27, 0.02) 0.11 0.0852
insight 0.9 (1.29) -0.2 (0.06) 1.0 (1.30) -0.4 (0.04) -0.1 (-0.26, 0.01) 0.21 0.0669
language–thought disorder 2.3 (0.61) -0.8 (0.08) 2.2 (0.66) -1.1 (0.06) -0.2 (-0.41, -0.05) 0.29 0.0109
increased motor activity – energy 2.9 (0.68) -1.1 (0.10) 2.9 (0.65) -1.4 (0.07) -0.3 (-0.55, -0.11) 0.32 0.0039
elevated mood 2.6 (0.96) -0.9 (0.09) 2.8 (0.88) -1.4 (0.06) -0.5 (-0.68, -0.28) 0.47 0.0001
sleep 2.3 (0.91) -0.9 (0.09) 2.4 (0.92) -1.3 (0.07) -0.4 (-0.66, -0.23) 0.47 0.0001
sexual interest 1.6 (1.20) -0.6 (0.08) 1.6 (1.17) -0.9 (0.06) -0.3 (-0.52, -0.13) 0.31 0.0013
content 4.4 (2.27) -1.7 (0.17) 4.4 (2.12) -2.3 (0.12) -0.5 (-0.89, -0.12) 0.21 0.0103
speech 4.5 (1.51) -1.9 (0.16) 4.4 (1.56) -2.5 (0.11) -0.6 (-0.94, -0.21) 0.28 0.0020
Note: aPatients with baseline PaNss hostility item scores 2.
Abbreviations: CI, confidence interval; ES, effect size; LS, least squares; LSMD, LS mean difference; MMRM, mixed-effects model for repeated measures; PANSS, Positive 
and Negative syndrome scale; sD, standard deviation; se, standard error of the mean; YMrs, Young Mania rating scale.
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